Central Nervous System Biomarkers Market Competitive Landscape, Growth Factors, Revenue Analysis Till 2027


According to MRFR analysis, the global Central Nervous System Biomarkers market is expected to register a CAGR of~13.0%from 2021 to 2027and hold a value of over ~USD 7,500 million by2027.

The global CNS biomarkers market is driven by several factors, such astechnological advancements, an increase in the use of biomarkers inthe diagnosis of neurodegenerative diseases, increasing research and development, and successful clinical trials. According to Alzheimer’s Disease International, in 2020, over 50 million people have dementia, where CNS disorders help in the diagnosis and prognosis of the disorders. Furthermore, recent technologies such as genomics and proteomics, and imaging technologies, several new biomarkers are being developed.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/9140

The key players are involved in new product launches, strategic agreements, and joint ventures to augment their market positions. For instance, in September 2020, Siemens Healthineers (Germany) announced a strategic collaboration with Novartis Pharma AG (Switzerland) for biomarker development for Multiple Sclerosis. Furthermore, new product approvals by the FDA are supplementing the market growth. For instance, in May 2019, the N170 CNS biomarker letter of intent was accepted by the FDA for autism spectrum disorder, submitted by Roche (Switzerland) for approval.

Regional Analysis

North America is expected to dominate the CNS biomarkers market in 2021, owing to the growing geriatric population, the adoption of the latest technologies for CNS disorder treatment, and key industry players across the region. According to the US Census Bureau, the country .constitutesaround 34% of the population aged 65 andolder; this number has increased by 3.2% over a year. Among the different regions in the Americas, Maine ranks first with the highest geriatric population. This is increasing the demand for CNS biomarkers across the region sinceagingincreases the risks of brain disorders and other CNS disorders. Furthermore, companies and research institutes are constantly innovating and discovering new technologies and biomarkers. This is supported by the presence of leading key players within the region as well as increasing R&D expenditure. For instance, as of August 2020, USD 23.1 million was funded for brain-related clinical and cancer control research in the US, according to the American Cancer Society.

In Europe, the increase in demand for personalized/precision medicine and the prevalence of neurological diseases in Europe are driving the CNS biomarkers market in the region. According to the report published in October 2020, in Europe, neurological disorders ranked third after cardiovascular diseases and cancer. Furthermore, another report published in July 2020 by King’s College London, by 2047, there will be 2.5 million cases of stroke in Europe, which is a 23% increase from 2017 data.

Asia-Pacific is expected to be the fastest-growing regional market in the forecast period due to factors such asa large customer base, high prevalence of CNS disorders, and improving healthcare infrastructure. China accounts for the highest number of stroke cases in the world, with 354 cases per 100,000 people in 2016, according to a report published in The Lancet in March 2019; this shows the immense application of CNS biomarkers in the region.

The rest of the world includes the Middle East, Africa, and Latin America. These regions are also facing an increase in neurological disorders, which is driving the CNS biomarkers market. For instance, according to a report from Alzheimer’s Disease International 2020, an estimated 6% of the 15 million older people (above the age of 50 years) in Brazil.

Segmentation

The global CNS biomarkers market has been segmented into type, application, and end user.

By type, the market has been segregated into safety biomarker,efficacy biomarker, validation biomarker, and others. The safety biomarker segment is expected to hold a considerable share of the market in 2020due to its importance in clinical trials. The majority of the clinical trials fail due to safety and toxicity issues.

Based on application, the global CNS biomarkers market has been classified intodrug discovery & development, personalized medicine,and others. Personalized medicine witnessed high growth as the emphasis on personalized medicine increases due to more effectiveness and risk of minimal side effects than present treatments.

Based on end user,the CNS biomarkers market is classified intodiagnostic labs, hospitals&clinics and research centers. Diagnostic Labs held asignificantmarket share in 2020 due toincreasing neurological disorders across the globe and the need for diagnosis for the same.

Key Players

Some of the key players in the global CNS biomarkers marketareThermo Fisher Scientific (US), Merck & Co. (US), AbaStarMDx Inc. (US), Abiant, Inc. (US), Avacta Group plc (UK), Diagenic Asa (Norway), Banyan Biomarkers (US), Avid Radiopharmaceuticals Inc. (US), and Acumen Pharmaceuticals Inc. (US) amongothers.

Access full report @ https://www.marketresearchfuture.com/reports/central-nervous-system-biomarkers-market-9140

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Have a Look at Related Reports:

Cataract Surgery Device Market - https://www.globenewswire.com/en/news-release/2019/07/26/1892126/0/en/Cataract-Surgery-Device-Market-Share-will-Recorded-More-than-4-5-billion-USD-Globally-at-Growing-CAGR-of-5-5-Till-2022-Industry-Statistical-Growth-Predictions-2019.html

Freeze Drying Equipment Market - https://www.globenewswire.com/en/news-release/2019/07/26/1892236/0/en/Freeze-Drying-Equipment-Market-to-Witness-Remarkable-Growth-with-a-CAGR-of-8-9-by-2024-Says-Market-Research-Future.html

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com


Location: New York, NY, USA

Comments

Post a Comment

Popular posts from this blog

Digital Pathology Market Research, Size, Revenue, Trends, Competitive Landscape Study & Analysis, Forecast To 2028

Image
  The growing number of innovations in the areas of pathology would further increase the size of the market to a great deal, in the next six years. According to MRFR, the Digital Pathology Market is expected to register a CAGR of 6.5% over the review period from 2021 to 2028 and expected to reach USD 1.4 Billion by 2028. Digital Pathology or Computational Pathology leverages completely new perceptions through data analysis, enabling pathologists to consult on treatment options. The rapidly evolving pathology sector is a key element of modern diagnostic practices. There have been several innovations and widespread adoption of digital pathology. It has long been realized that the traditional histopathology is inefficient as it exposes samples to various handlers, increasing the scope for human error. The digital pathology, on the other hand, eliminates the risk factors, while also providing the pathologist with the necessary images and clinical information to generate the most a...
Read more

Structural Heart Devices Market Size, Key Player Revenue, SWOT, PEST & Porter’s Analysis Till 2027

Image
Structural heart diseases   are problems associated with the valves or tissues of the heart. These diseases may be congenital or might be acquired later in life. Structural heart diseases include cardiomyopathy, myocarditis, aortic valve stenosis, heart valve disease, atrial septal defect, mitral valve regurgitation, and others. As per the latest report of Market Research Future (MRFR), the structural heart devices market is poised to expand at CAGR of 10.4% over the forecast period. The  structural heart devices market  is primarily driven by a radical rise in the incidence rate of non-coronary heart disorders, increased demand for minimally invasive surgical procedures, and improving reimbursement schemes. In the past few years, tremendous advances have been achieved with respect to the understanding of these diseases, and accordingly, therapeutic modalities have been developed. A number of clinical trials and technology developments are underway, which is likely to pro...
Read more

Anal Fissure Treatment Market Competitive Landscape, Growth Factors, Revenue Analysis Till 2030

Image
  The global  anal fissure treatment market  is expected to rise and touch a valuation of USD 2,526.5 million by 2023, at a 7.6% CAGR during the forecast period. Anal fissures are small tears near the mucosal lining of the anus. Deeper cuts may take a combination of oral and topical medicine to alleviate the pain. The anal fissure treatment market is expected to thrive owing to the booming pediatric and geriatric patient pool. Advances in technology coupled with various treatment options is likely to lead to a windfall for the market over the forecast period. High incidence of constipation is predicted to drive the need for anal fissure treatments. This is backed by vulnerability of the elderly which find it difficult to pass stools properly. According to the American Gastroenterological, nearly 33% of Americans above 60 experience the condition. Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/3841 Unhealthy lifestyles adopted by pat...
Read more